Medicines

Fulltext search

For help on how to get the results you want, see our search tips.

Search results

Categories

Human (232) Apply Human filter Veterinary (8) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Withdrawn applications Remove Withdrawn applications filter Paediatric investigation plans Remove Paediatric investigation plans filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Summaries of opinion (3) Apply Summaries of opinion filter Orphan designations (42) Apply Orphan designations filter Referrals (4) Apply Referrals filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (148) Apply Authorised filter Refused (2) Apply Refused filter Withdrawn (32) Apply Withdrawn filter

ATC code

Species

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

Withdrawal type

Initial authorisation (4) Apply Initial authorisation filter Post-authorisation (1) Apply Post-authorisation filter

Withdrawal date

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (7) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (32) Apply PM: decision on the application for modification of an agreed PIP filter RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) (1) Apply RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s) filter W: decision granting a waiver in all age groups for all conditions or indications (10) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (10) Apply Yes filter

Compliance procedure number

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Exceptional circumstances Remove Exceptional circumstances filter Additional monitoring (597) Apply Additional monitoring filter Conditional approval (83) Apply Conditional approval filter Generic (341) Apply Generic filter Orphan medicine (296) Apply Orphan medicine filter

Related medicine

Therapeutic area

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

241 results

Remove all filtersRemove all filters

Medicine type Accelerated assessment Remove Accelerated assessment filter Exceptional circumstances Remove Exceptional circumstances filter Biosimilar Remove Biosimilar filter

Medicine Paediatric investigation plans Remove Paediatric investigation plans filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Direct healthcare professional communication Remove Direct healthcare professional communication filter Withdrawn applications Remove Withdrawn applications filter

Sort by

List item

Human medicine European public assessment report (EPAR): Ceplene (updated)

Histamine dihydrochloride, Leukemia, Myeloid, Acute
Date of authorisation: 07/10/2008, , , Revision: 12, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Filgrastim Hexal (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 06/02/2009, , Revision: 20, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Ranivisio (updated)

ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 25/08/2022, , , Revision: 2, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Yuflyma (updated)

adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 11/02/2021, , Revision: 9, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Zarzio (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 06/02/2009, , Revision: 21, Authorised, Last updated: 30/01/2023
List item

Human medicine European public assessment report (EPAR): Coagadex (updated)

Human coagulation factor X, Factor X Deficiency
Date of authorisation: 16/03/2016, , , Revision: 9, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Herzuma (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 09/02/2018, , , Revision: 18, Authorised, Last updated: 25/01/2023
List item

Human medicine European public assessment report (EPAR): Pelgraz (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 21/09/2018, , , Revision: 8, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Omnitrope (updated)

somatropin, Turner Syndrome; Prader-Willi Syndrome; Dwarfism, Pituitary
Date of authorisation: 12/04/2006, , Revision: 21, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Ratiograstim (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 15/09/2008, , Revision: 15, Authorised, Last updated: 23/01/2023
List item

Human medicine European public assessment report (EPAR): Amgevita (updated)

adalimumab, Arthritis, Psoriatic; Colitis, Ulcerative; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 21/03/2017, , Revision: 11, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Praxbind (updated)

idarucizumab, Hemorrhage
Date of authorisation: 20/11/2015, , Revision: 11, Authorised, Last updated: 18/01/2023
List item

Human medicine European public assessment report (EPAR): Remsima (updated)

infliximab, Arthritis, Psoriatic; Spondylitis, Ankylosing; Colitis, Ulcerative; Psoriasis; Crohn Disease; Arthritis, Rheumatoid
Date of authorisation: 10/09/2013, , Revision: 31, Authorised, Last updated: 17/01/2023
List item

Human medicine European public assessment report (EPAR): Atriance (updated)

nelarabine, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Date of authorisation: 22/08/2007, , , Revision: 26, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

tafamidis, Amyloidosis
Date of authorisation: 16/11/2011, , , , Revision: 23, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): Hukyndra (updated)

adalimumab, Arthritis, Psoriatic; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Hidradenitis Suppurativa; Psoriasis; Spondylitis, Ankylosing; Uveitis
Date of authorisation: 15/11/2021, , Revision: 3, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): Orphacol (updated)

cholic acid, Digestive System Diseases; Metabolism, Inborn Errors
Date of authorisation: 12/09/2013,
Date of refusal: 25/05/2012, , , , Revision: 12, Authorised, Last updated: 16/01/2023
List item

Human medicine European public assessment report (EPAR): Nivestim (updated)

filgrastim, Neutropenia; Hematopoietic Stem Cell Transplantation; Cancer
Date of authorisation: 07/06/2010, , Revision: 26, Authorised, Last updated: 12/01/2023
List item

Human medicine European public assessment report (EPAR): Ebvallo (updated)

Tabelecleucel, Lymphoproliferative Disorders
Date of authorisation: 16/12/2022, , , , Authorised, Last updated: 12/01/2023
List item

Human medicine European public assessment report (EPAR): Libmyris (updated)

adalimumab, Arthritis, Rheumatoid; Arthritis, Juvenile Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Psoriasis; Hidradenitis Suppurativa; Crohn Disease; Colitis, Ulcerative; Uveitis
Date of authorisation: 12/11/2021, , Revision: 1, Authorised, Last updated: 11/01/2023
List item

Human medicine European public assessment report (EPAR): Benepali (updated)

etanercept, Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis
Date of authorisation: 13/01/2016, , Revision: 18, Authorised, Last updated: 06/01/2023
List item

Human medicine European public assessment report (EPAR): Mvasi (updated)

bevacizumab, Carcinoma, Renal Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms
Date of authorisation: 15/01/2018, , Revision: 14, Authorised, Last updated: 05/01/2023
List item

Human medicine European public assessment report (EPAR): Onbevzi (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 11/01/2021, , , Revision: 3, Authorised, Last updated: 05/01/2023
List item

Human medicine European public assessment report (EPAR): Byooviz (updated)

ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Myopia, Degenerative
Date of authorisation: 18/08/2021, , , Revision: 5, Authorised, Last updated: 05/01/2023
List item

Human medicine European public assessment report (EPAR): Zirabev (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 14/02/2019, , , Revision: 12, Authorised, Last updated: 05/01/2023

Load more

241 results

Human medicine European public assessment report (EPAR): Ceplene (updated)

Human medicine European public assessment report (EPAR): Filgrastim Hexal (updated)

Human medicine European public assessment report (EPAR): Ranivisio (updated)

Human medicine European public assessment report (EPAR): Yuflyma (updated)

Human medicine European public assessment report (EPAR): Zarzio (updated)

Human medicine European public assessment report (EPAR): Coagadex (updated)

Human medicine European public assessment report (EPAR): Herzuma (updated)

Human medicine European public assessment report (EPAR): Pelgraz (updated)

Human medicine European public assessment report (EPAR): Omnitrope (updated)

Human medicine European public assessment report (EPAR): Ratiograstim (updated)

Human medicine European public assessment report (EPAR): Amgevita (updated)

Human medicine European public assessment report (EPAR): Praxbind (updated)

Human medicine European public assessment report (EPAR): Remsima (updated)

Human medicine European public assessment report (EPAR): Atriance (updated)

Human medicine European public assessment report (EPAR): Vyndaqel (updated)

Human medicine European public assessment report (EPAR): Hukyndra (updated)

Human medicine European public assessment report (EPAR): Orphacol (updated)

Human medicine European public assessment report (EPAR): Nivestim (updated)

Human medicine European public assessment report (EPAR): Ebvallo (updated)

Human medicine European public assessment report (EPAR): Libmyris (updated)

Human medicine European public assessment report (EPAR): Benepali (updated)

Human medicine European public assessment report (EPAR): Mvasi (updated)

Human medicine European public assessment report (EPAR): Onbevzi (updated)

Human medicine European public assessment report (EPAR): Byooviz (updated)

Human medicine European public assessment report (EPAR): Zirabev (updated)